Sistema de Información Esencial en Terapéutica y Salud

@SIETES7

Última actualización: 17/2/2020
SIETES contiene 92902 citas

 
 
 1 a 20 de 113 siguiente >>
Presentar resultados
Seleccionar todas
1. Cita con resumen
Campins M, Moraga-Llop FA. Novetats en el calendari vacunal de Catalunya 2016. Butlletí d'Informació Terapèutica 2016;27:60-5. [Ref.ID 101346]
2. Cita con resumen
Read RC, Baxter D, Chadwick DR, Faust SN, Finn A, Gordon SB, Heath P, Lewis DJM, Pollard AJ, Turner DPJ, Bazaz R, Ganguli A, Havelock T, Neal KR, Ikike IO, Morales-Aza B, Patel K, Snape MD, Williams J, Gilchrist S, Gray SJ, Maiden MCJ, Toneatto D, Wang H, McCarthy M, Dull PM, Borrow R. Effect of a quadrivalent meningococcal ACWY glycoconjugate or a serogroup B meningococcal vaccine on meningococcal carriage: an observer-blind, phase 3 randomised clinical trial. Lancet 2014;384:2123-31. [Ref.ID 98454]
3. Cita con resumen
Martinón-Torres F. Immunisation against meningococcus B: the case of Spain. Lancet 2013;382:1552-3. [Ref.ID 96522]
4. Cita con resumen
Aldea A, García Sánchez-Colomer M, Fernández Quintana E, García Sáiz M. Paediatric adverse drug reactions reported to the Spanish Pharmacovigilance System from 2004 to 2009. Eur J Clin Pharmacol 2012;68:1329-38. [Ref.ID 93650]
5. Cita con resumen
Anónimo. Vaccines and pregnancy. Med Lett Drugs Ther 2011;53:94-6. [Ref.ID 91857]
6.Enlace a cita original
Visintin C, Mugglestone MA, Fields EJ, Jacklin P, Murphy MS, Pollard AJ, on behalf of the Guideline Development Group. Management of bacterial meningitis and meningococcal septicaemia in children and young people: summay of NICE guidance. BMJ 2010;341:92-4. [Ref.ID 88874]
7.
Tan LKK, Carlone GM, Borrow R. Advances in the development of vaccines against Neisseria meningitidis. N Engl J Med 2010;362:1511-20. [Ref.ID 88302]
8. Cita con resumen
Moloney A. Latin America faces hurdles in health research. Lancet 2009;374:1053-4. [Ref.ID 86847]
9. Cita con resumen
Platt R, Wilson M, Chan A, Benner JS, Marchibroda J, McClellan M. The new Sentinel Network — Improving the evidence of medical-product safety . N Engl J Med 2009;361:645-7. [Ref.ID 86387]
10.Tiene citas relacionadas
Haber P, Sejvar J, Mikaeloff Y, DeStefano F. Vaccines and Guillain-Barré syndrome. Drug Saf 2009;32:309-23. [Ref.ID 85764]
12.Tiene citas relacionadas
Theilen U, Wilson L, Wilson G, Qureshi S, Simpson D, on behalf of the Guideline Development Group. Management of invasive meningococcal disease in children and young people: summary of SIGN guidelines. BMJ 2008;336:1367-70. [Ref.ID 83272]
13.Tiene citas relacionadas
14.Tiene citas relacionadas
Snape MD, Perrett KP, Ford KJ, John TM, Pace D, Yu LM, Langley JM, McNeil S, Dull PM, Ceddia F, Anemona A, Halperin SA, Dobson S, Pollard AJ. Immunogenicity of a tretavalent meningococcal glycoconjugate vaccine in infants. A randomized controlled trial. JAMA 2008;299:173-84. [Ref.ID 82008]
15. Cita con resumen
Loewenberg S. Drug company trials come under increasing scrutiniy. Lancet 2008;371:191-2. [Ref.ID 81983]
17.Tiene citas relacionadas
Gardner P. Prevention of meningococcal disease. The author replies. N Engl J Med 2007;356:525-6. [Ref.ID 79087]
18.Tiene citas relacionadas
Senanayake SN. Prevention of meningococcal disease. N Engl J Med 2007;356:525. [Ref.ID 79086]
19.Tiene citas relacionadas
Booy R, Viner R. Prevention of meningococcal disease. N Engl J Med 2007;356:524-5. [Ref.ID 79085]
20. Cita con resumen
Rothwell PM. Funding for practice-oriented clinical research. Lancet 2006;368:262-6. [Ref.ID 77447]
Seleccionar todas
 
 1 a 20 de 113 siguiente >>